SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently trending due to a major contract win with the U.S. Space Force for suborbital launches, a development that highlights the company's growing role in national security and defense infrastructure. While the community is actively celebrating this validation of Rocket Lab's execution, the stock price remains heavily tethered to broader space sector volatility and the performance of larger peers, leading to mixed sentiment among investors frustrated by the muted market reaction to positive news.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. (CRML) is currently facing intense community debate and market volatility as investors weigh the potential of the Tanbreez project against concerns regarding management transparency, recent tender bid controversies, and ongoing share dilution. While some investors view the company as a strategic, highly undervalued play for critical mineral independence, others remain skeptical, pointing to delays, confusing communication regarding the Kenya bid, and a history of underperforming expectations.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors and the Duchenne muscular dystrophy community prepare for a high-stakes FDA advisory committee meeting to review the companys therapy for DMD cardiomyopathy. Discussions are focused on the clinical data supporting both skeletal and cardiac benefits, with the community actively lobbying for a broad label and bracing for volatility ahead of the panel's decision.

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is rallying sharply following a significant $53 million private placement announcement, sparking intense retail interest and heavy trading volume. The community is actively debating the potential for further momentum versus the risks of dilution, with many focused on whether the stock can sustain its breakout levels.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is currently trending as investors weigh volatile crude oil prices against the latest geopolitical developments regarding U.S.-Iran negotiations and ongoing regional instability. The community is actively debating whether recent diplomatic headlines are a genuine catalyst for a long-term supply shift or merely speculative noise, with many traders focusing on the impact of potential supply gluts and the effectiveness of energy-related ceasefire agreements.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending amid investor volatility following a conservative full-year revenue outlook and a recent earnings miss, with the community actively debating whether the dip represents a long-term buying opportunity or a sign of persistent execution challenges. While discussions focus on aggressive sales team expansion and the long-term potential of the Vevye and Iheezo product lines, investors are closely watching for signs that management can better align messaging with actual financial results.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as investors debate the impact of newly launched market-moving APIs and the company's financial performance, while social sentiment remains heavily polarized by the political discourse surrounding the brand. Community discussion is dominated by intense debates over the efficacy of trade policies, ongoing geopolitical tensions, and the platform's role in political advocacy.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X ETF

Direxion Daily S&P Biotech Bear 3X Shares

LABD is experiencing significant volatility and high trading volume as investors react to the biotech sector's struggle with rising inflation, elevated oil prices, and broader market uncertainty. Community discussions remain polarized, with many traders debating the effectiveness of shorting the sector through leveraged ETFs while monitoring key technical resistance levels in the XBI biotech index.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is trending as community members rally behind its position as a leader in real-world asset (RWA) tokenization, with many investors anticipating long-term growth driven by institutional interest and upcoming regulatory milestones. While bullish sentiment dominates the discussion regarding its utility and potential for a significant bull run, some participants emphasize the importance of monitoring governance proposals and potential supply shifts that could influence the asset's trajectory.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is facing intense selling pressure following a leadership transition and negative sentiment regarding competitive threats from newer multiple myeloma combo therapies. Investors remain cautious as they monitor how the company will maintain its CARVYKTI momentum and leverage its in-vivo pipeline to justify a potential premium valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


theeastendthriftstore

Mega888 APK